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Introduction: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vascu-
litis is an autoimmune disease that can affect multiple organs, the kidney being 
one of the most affected. Apart from the diagnostics value of ANCA, they have 
also been advocated as biomarkers of the disease activity. Recently, the genetic 
changes found in polyangiitis associated with serine-protease proteinase 3 (PR3)-
ANCA or myeloperoxidase (MPO)-ANCA raised the possibility of immune-patho-
genic and therapeutic differences. 
Objective: To identify differences in the number of relapses, inflammatory mark-
ers, outcomes and renal histology related to the types of ANCA. To analyze the 
implications of ANCA titers in prognosis. 
Method: A retrospective observational study in a Portuguese tertiary hospital. 
Results: There were no differences in the progression of renal function, histo-
logical pattern and initial treatment with regard to ANCA subtypes. As for the 
evaluated parameters, there were no significant differences according to the types 
of ANCA, except for mean CRP values within the normal range, which was 6.3±1.3 
mg/L for MPO-ANCA and 12.4±10.14 mg/L for PR3-ANCA (p=0.04). We found 
that 66.7% of the MPO-ANCA-positive showed no relapses versus 40% in the case 
of PR3-ANCA-positive. There was no correlation between the ANCA titers at 
presentation, during remission, and in the last evaluation, and the number of 
relapses. 
Conclusion: PR3-ANCA patients have a mean CRP value within the normal 
range significantly higher than that of MPO-ANCA patients (p=0.04), which 
seems to reveal greater inflammatory activity in the first.
Keywords: anti-neutrophil cytoplasmic antibody-associated vasculitis, peroxi-
dase, serine proteases.
introduction
Anti-neutrophil cytoplasmic antibody (ANCA)-associated 
vasculitis is an autoimmune disease that can affect different 
organs and present multiple symptoms. This group includes 
granulomatosis with polyangiitis (GPA), microscopic 
polyangiitis (MPA), eosinophilic granulomatosis with poly-
angiitis (EGPA) and vasculitis limited to the kidney (KLD, 
Kidney Limited Disease).1,2 In addition to these, ANCA are 
also detected in other vasculitic diseases, such as drug-in-
duced systemic vasculitis and other autoimmune diseases.3
The term “ANCA-associated vasculitis” (AAV) com-
bines histological and clinical similarities, the widespread 
use of ANCA antibodies as a diagnostic marker, and its 
pathogenic potential. The main fluoroscopy staining pat-
terns are diffuse granular cytoplasmic (C-ANCA) and peri-
nuclear (P-ANCA); the first is due to the presence of au-
toantibodies bound to serine-protease proteinase 3 
(PR3-ANCA), while the latter can be caused by antibod-
ies against many antigens, including myeloperoxidase 
(MPO-ANCA), which is the most frequent in AAV.4
The role of ANCA in the diagnosis of AAV is indis-
putable, and these antibodies have been advocated as bio-
markers of disease activity.5 The complexity of the role of 
ANCA is associated with the plurality of genetic, epigen-
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etic and environmental factors.6 Genetic differences in 
polyangiitis caused by PR3-ANCA and MPO-ANCA may 
have immune-pathogenic and therapeutic implications.7
The kidney is one of the organs most affected in AAV. 
In GPA and MPA, there is renal involvement in about 71-
88% of cases, and 25% in EGPA.2 Rapidly progressive re-
nal failure is the most typical kidney presentation, com-
bining a rapid deterioration in renal function with micro 
or macro hematuria and often with non-nephrotic pro-
teinuria.1 About 35% of these patients require dialysis at 
presentation.8
Renal biopsy is recommended in order to confirm the 
diagnosis and prognosis of kidney damage.1 The percent-
age of normal glomeruli is a powerful predictor, possibly 
the best predictor of histologic outcomes in the short and 
long term.9 Nevertheless, renal disease activity indicators, 
such as increased serum creatinine and/or presence of he-
maturia, and the value or worsening of proteinuria and 
erythrocyte cylinders in urine, have been identified.10
In short, ANCA antibodies have a central involvement 
in the pathogenesis of these vasculites, but little is known 
about their prognostic value at the date of diagnosis and 
progression in the course of disease. Thus, we intend to 
identify differences in the number of relapses, inflamma-
tory markers, outcomes and renal histologic pattern found 
with the different types of ANCA (PR3-ANCA, MPO-AN-
CA). In addition, we intend to analyze the implications 
of ANCA titers at baseline and their progression over the 
course of disease, including the number of relapses pre-
sented by patients.
Method
A retrospective study of 29 patients followed at the Ne-
phrology Service of Centro Hospitalar do Porto, Hospi-
tal de Santo António, between 1997 and 2014, identified 
with AAV with renal involvement.
All patients had renal biopsies confirming the diagno-
sis, and disease criteria were based on international recom-
mendations (EUVAS): history of chronic inflammatory dis-
ease for at least 4 weeks ruling out other potential causes, 
such as infection or malignancy, and support of histologi-
cal features on biopsy and/or enzyme-linked immunosor-
bent assay (ELISA) positive for PR3 or MPO antibodies.11
Remission was considered as the absence of symp-
toms, i.e., Birmingham vasculitis activity score (BVAS)=0, 
under a low dose of prednisolone (≤ 10 mg/day) for at 
least 6 months.12
Major relapse was defined as recurrence or de novo ap-
pearance of disease activity threatening a vital organ or 
the patient’s life, and which could not be treated solely 
with increased doses of corticosteroids. Minor relapse, in 
turn, corresponded to other activities of the disease.11,13 
Proteinuria at presentation was classified, based on a 24-
hour urine sample, into nephrotic (≥ 3.5 g/24h), non-ne-
phrotic (300 mg/24h to 3.5 g/24h), and microalbumin-
uria (30 to 300 mg/24h).
Up to six values were selected for changes in titers of 
ANCA antibodies, erythrocyte sedimentation rate (ESR), 
C-reactive protein (CRP) and indicators of renal injury 
and dysfunction at time intervals of about 4 months, dur-
ing remissions of each patient. Again, the same parame-
ters for each recurrence.
ANCA and antinuclear antibodies titers were obtained 
using ELISA method. BVAS score was calculated using 
Calculater – V314 software, considering the symptoms de-
scribed in the patient’s clinical process.
Chi-square and Fisher tests were used in the analysis 
of categorical variables, nonparametric Mann-Whitney test 
was used to compare two independent samples, and Krus-
kal-Wallis test allowed to compare differences between vari-
ables with more than two independent samples using SPSS 
22.0 software. The results were considered statistically sig-
nificant at the significance level of 5% (p=0.05).
results
Of the 29 patients, at admission, 24 were positive for 
MPO-ANCA and only five for PR3-ANCA; 18 had ANCA 
titers ≥ 1/640, nine had titers at 1/320, and two ≤ 1/80. 
As for histology in renal biopsy, 14 revealed a progressive 
pattern, five had sclerotic pattern, and 10 a mixed pat-
tern. Other demographic data as well as the outcomes are 
shown in Table 1. 
Of the 15 patients on renal replacement therapy, three 
underwent renal transplantation while the rest remained 
on hemodialysis. Mortality rates were 0% after 1 year of 
follow-up, one death (3.4%) after 3 years, and three deaths 
(10.3%) after 7 years.
In renal histology of PR3-ANCA-positive patients, 80% 
(n=4) showed a progressive pattern, while 20% (n=1) had a 
sclerotic pattern. Among the MPO-ANCA-positive patients, 
41.7% (n=10) revealed a progressive pattern, 41.7% (n=10) 
a mixed pattern and 16.7% (n=4) had a sclerotic pattern.
Regarding ANCA titers at presentation, 75% (n=18) 
of the MPO-ANCA-positive had ANCA ≥ 1/640, while 
25% (n=6) presented 1/320. As for the PR3-ANCA-posi-
tive patients, 60% (n=3) showed titers at 1/320 and 40% 
(n=2) showed titers ≤ 1/80.
Regarding the number of relapses, 40% (n=2) of the 
PR3-ANCA-positive did not recur, and 60% (n=3) had re-
lapsed once. Among the MPO-ANCA-positive, 66.7% 
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TABLE 1 Demographic data of the sample and events.
Variable  Result
Average age (years) - diagnosis (M±sd) 58.38±17.45 (30-87)
Gender (n;%)
Women 55.2% (16)
Men 44.8% (13)
Mean follow-up in years (M±sd) 4.11±3.34 (1.5-12) Med=3.0
Serum creatinine at baseline (mg/dL) (M±sd) 5.2±2.98 (1.74-13) Med=4.6
CRP at baseline (mg/L) (M±sd) 36.36±54.23 (0.9-181) Med=9.5
ESR at baseline (mm/h) (M±sd) 87.2±21.32 (46-126) Med=89.0
BVAS at baseline (M±sd) 16.52±3.97 (12-29)
Types of ANCA (n;%)
MPO 82.76% (24)
PR3 17.24% (5)
ANCA titers (n;%) ≥1/640 62.1% (18)
1/320 31.0% (9)
≤1/80 6.9% (2)
ANA (n;%) Positive 48.3% (14)
Progressive 48.3% (14)
Histological patterns of biopsy (n;%) Sclerotic 17.2% (5)
Mixed 34.5% (10)
Proteinuria at baseline (n;%) Non-nephrotic 27.6% (8)
Nephrotic 31.0% (9)
Microalbuminuria 34.5% (10)
Absent 6.9% (2)
Microscopic hematuria at baseline (n;%) Present 96.6% (28)
Renal symptoms at baseline (n;%) Present 44.8% (13)
Pulmonary symptoms at baseline (n;%) Present 31.0% (9)
Number of relapses (n;%) 0 62.1% (18)
1 31.0% (9)
>2 6.8% (2)
Initial treatment (n;%) Corticosteroids + cyclophosphamide 58.6% (17)
Corticosteroids + cyclophosphamide + plasmapheresis 41.4% (12)
RRT 60% (15)
Outcome (n;%) Remission 28.0% (7)
Death 12.0% (3)
CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; BVAS: Birmingham vasculitis activity score; ANCA: anti-neutrophil cytoplasmic antibody; MPO: myeloperoxidase; PR3: proteinase; 
ANA: antinuclear antibodies; RRT: renal replacement therapy; Med: median; M: mean; sd: standard deviation.
(n=16) did not recur, 25% (n=6) had one relapse, and 8.4% 
(n=2) showed at least two relapses.
50% (n=12) of the MPO-ANCA-positive patients had re-
nal involvement at presentation, and 29.2% (n=7) had pul-
monary involvement. There was one MPO-ANCA-positive 
patient who presented renal and pulmonary symptoms si-
multaneously. Among the PR3-ANCA-positive patients, only 
one (20%) had renal involvement at the time of diagnosis, 
and two (40%) had pulmonary involvement (p>0.05).
Regarding BVAS presentation, the mean value of cre-
atinine at baseline and at the last evaluation, and the mean 
value of ESR at baseline and intervals, there were no sta-
tistically significant differences in terms of types of ANCA 
(p>0.05) (Table 2). The same was true for CRP value at base-
line. The mean value of CRP within the intervals for MPO-
ANCA-positive patients was 6.3±6.4 mg/L (Med=5.00), 
while for PR3-ANCA-positive individuals it was 12.4±10.1 
mg/L (Med=8.00), with a p=0.04 (Table 2).
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As for proteinuria, nine (37.5%) of the MPO-ANCA-pos-
itive individuals had microalbuminuria, six (25%) had 
non-nephrotic proteinuria, and nine (37.5%) had nephrot-
ic proteinuria. Among the PR3-ANCA-positive patients, 
two (40%) did not have proteinuria, one (20%) had non-
nephrotic proteinuria, and two (40%) had nephrotic pro-
teinuria. An identical distribution of these variables be-
tween the two types of ANCA was found.
At the end of follow-up, 65% (n=13) of MPO-ANCA-
positive patients were on renal replacement therapy, 20% 
(n=4) were in remission, and 15% (n=3) died. 40% (n=2) 
of the PR3-ANCA-positive patients were under treatment 
with renal replacement therapy, and 60% (n=3) were in 
remission.
In the last assessment of ANCA titers, we obtained 
the following values: 31% (n=9) were negative, 34.5% (n=10) 
showed titers ≤ 1/80, 13.8% (n=4) had titers equal to 1/160 
and 13.8% (n=4) had titers ≥ 1/320; two other patients 
did not have ANCA counts (Table 3).
TABLE 3 Progression of ANCA titers (first assessment vs. 
last assessment) and relative and absolute frequencies of 
relapse by ANCA titers at presentation.
ANCA titers at presentation
≥1/640 
(n,%)
≥1/640 
(n,%)
≥1/640 
(n,%)
Last 
ANCA 
titers 
evaluated
Negative 6 (35.3) 2 (25) 1 (50)
≤1/80 6 (35.3) 3 (37.5) 1 (50)
1/160 3 (17.6) 1 (12.5) 0
≥1/320 2 (11.8) 2 (25) 0
Total 
number of 
relapses
0 12 (66.7) 6 (66.7) 0
1 4 (22.2) 3 (33.3) 2 (100)
2 1 (5.6) 0 0
3 1 (5.6) 0 0
ANCA: anti-neutrophil cytoplasmic antibody.
Despite the non-applicability of statistical tests, by ana-
lyzing the frequency displayed as Table 3, we found that 
patients with higher ANCA titers at presentation became 
negative more often and had a greater decline over the 
course of the evaluation.
With regard to the relationship between relapses and 
ANCA titers at presentation, based on the frequency anal-
ysis presented on Table 3, we have not found a correla-
tion between the ANCA titers and relapses, i.e., lower 
ANCA titers are not predictors of non-recurrence. The 
same is true for ANCA titers during remission and at the 
last evaluation.
discussion
ANCA antibodies have an indisputable role in the diag-
nosis of AAV.5 In a study conducted by Lionaki et al., most 
of the patients with KLD were MPO-ANCA-positive (81%), 
while in patients with destructive lesions of the upper air-
way PR3-ANCA prevails (94%). Thus, when vasculitis ex-
pands from limited to the kidney to a form that involves 
the gastrointestinal or respiratory tract, the frequency of 
MPO-ANCA decreases at the expense of increased PR3-
ANCA.15
In our study, where all patients had renal involvement, 
82.8% of patients were MPO-ANCA-positive, which is in 
line with the results found in other studies. However, only 
50% of patients with MPO-ANCA showed renal involve-
ment at presentation. 40% of the PR3-ANCA-positive pa-
tients presented with pulmonary involvement.
Positive ANCA titers have a sensitivity and specificity 
of about 90% for the diagnosis of pauci-immune focal nec-
rotizing glomerulonephritis. The specificity of ANCA for 
MPO and PR3 can be detected in 85-90% of patients.16 
This result supports the role of ANCA antibodies in the 
pathogenesis of vasculitis, with several clinical and genet-
ic evidence, and tests backing it up.5,16 Serum determina-
TABLE 2 List of types of ANCA antibodies with the mean values for BVAS at baseline, creatinine at baseline, creatinine at 
last evaluation, CRP at baseline, CRP within the interval, ESR at baseline and ESR within the interval.
MPO (M, sd) PR3 (M, sd) p
BVAS at baseline 16.1 (4.03) 18.6 (3.2) 0.171
Serum creatinine at baseline (mg/dL) 5.3 (3.1) 4.7 (2.6) 0.885
Serum creatinine at last evaluation (mg/dL) 4 (2.2) 2.4 (2.1) 0.347
CRP at baseline (mg/L) 37.3 (58.1); Med=7.9 32 (33.7); Med=16.3 0.106
CRP within interval (mg/L) 6.3 (6.4); Med=5.0 12.4 (10.1); Med=8.0 0.04
ESR at baseline (mm/h) 85.3 (20.3); Med=88.0 97 (27.4); Med=100.5 0.317
ESR within interval (mm/h) 47.6 (28); Med=42.0 38.5 (27.7); Med=25.5 0.701
BVAS: Birmingham vasculitis activity score; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; ANCA: anti-neutrophil cytoplasmic antibody; MPO: myeloperoxidase; PR3: proteinase; M: 
mean; sd: standard deviation; Med: median.
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tion of ANCA titers in the assessment of disease activity 
remains a controversial topic in different studies. A meta-
analysis conducted by Rainer Birck et al. concludes that, 
in the literature, serum monitoring ANCA titers is char-
acterized by great clinical and methodological heteroge-
neity, and only a minority of studies is designed optimal-
ly to evaluate the accuracy of this parameter.17 In an article, 
Salama and Rees16 state that in some randomized prospec-
tive clinical trials and meta-analyzes neither the presence 
nor the titers of MPO or PR3 antibodies consistently cor-
relate with disease activity or clinical response to treat-
ment, and they are not predictors of clinical relapse.
In our study, we observed that there is no pattern of 
relationship between ANCA titers and the number of re-
lapses. Even patients with negative ANCA titers during 
remission had recurrences. Regarding the progression of 
ANCA titers from the date of diagnosis to the last evalu-
ation, these tended to decline or remain constant regard-
less of the clinical outcome of patients.
According to Savige et al. ANCA titers are often high 
at presentation, declining with treatment and eventual-
ly becoming negative in many patients, after 6 months or 
so of treatment. According to the authors, several stud-
ies show that an increase in ANCA titers precedes, be-
tween 3 and 6 months, at least half of the relapses;18 how-
ever, they do not mention the possibility of increases 
occurring in patients with negative titers. However, in a 
meta-analysis conducted by Gunnar Tomasson et al. and 
in the study performed by Sidy Seck et al., both the in-
crease and persistence of ANCA titers during remission 
of vasculitis were no more than moderate predictors of 
recurrence risk, which led to the conclusion that routine 
assessment of ANCA titers does not affect significantly 
the estimated clinical risk.5,19 But once again the possi-
bility of relapse with negative or declining ANCA titers 
is not evaluated.
In our cohort, the MPO-ANCA-positive patients had 
mean CRP values within the intervals significantly lower 
than those of PR3-ANCA-positive patients; also, 66.7% of 
the MPO-ANCA-positive showed no recurrence versus 40% 
among the PR3-ANCA-positive. This can translate a stron-
ger inflammatory response in PR3-ANCA-positive patients 
and thus justify the observation by Sophia Lionaki et al.15 
In her article, ANCA antibody specificity was predictive of 
relapse. Our group of PR3-ANCA patients had almost 
twice the probability to have recurrences than the MPO-
ANCA patients (p=0.04). The authors conclude that clas-
sifications and diagnostic systems that incorporate ANCA 
specificity provide a more useful tool for predicting recur-
rences than the pathological clinical categories alone.
Given that the course of disease after initial treatment 
is highly variable, and the fact that markers such as ANCA 
titers and non-specific inflammatory markers (CRP and 
ESR) have limitations, the research of new biomarkers is 
fundamental. Monach et al., among others, have identi-
fied three biomarkers, CXCL13, MMP-3 and TIMP-1, 
which stand out due to their ability to distinguish active 
AAV better than other reference markers studied, includ-
ing CRP and ESR.20
Renal morphology of ANCA-negative patients with 
pauci-immune focal glomerulonephritis is indistinguish-
able from that of ANCA-positive patients according to 
Salama and Rees, raising the question of what the etiol-
ogy of injury in the absence of these antibodies is. Thus, 
it seems highly likely that additional factors are required 
for AAV expression, leading to the need to analyze the 
role of newer described autoantibodies as well as their 
specificities for LAMP-2, plasminogen and moesin.16
In our study, we did not verify differences in serum 
creatinine at baseline, final serum creatinine and BVAS 
at baseline for the different types of ANCA. This is in line 
with other studies, namely the study by Clara Day et al., 
which did not reveal a correlation between levels of cre-
atinine at baseline and ANCA subtypes.21
A study of 100 biopsies from patients with glomeru-
lonephritis associated with ANCA antibodies stressed 
that the histologic classification at presentation is corre-
lated with outcomes. Patients with sclerotic glomerulo-
nephritis have worse renal function at diagnosis, with no 
significant improvement at 5 years. If more than 50% of 
the kidney is sclerotic, immunosuppression does not ap-
pear useful. Patients with focal disease and good renal 
function at baseline maintain good function after 5 years 
of treatment. Patients with classic progressive pattern 
present with rapidly progressive glomerulonephritis and 
worse renal function. However a considerable improve-
ment is found after 5 years.8 In our review we found no 
differences between histological patterns and ANCA sub-
types, which can be justified by a small number of cases.
Flossmann et al. found no differences in survival of 
patients with GPA and MPA.22 Again, noting that we did 
not classify our patients as small vessel vasculitis subtype, 
our results are in line with those obtained in the study 
mentioned above, since there were no differences in out-
comes relative to ANCA subtype.
Immunosuppressive therapy has significantly im-
proved the prognosis, and the mortality rate has decreased 
as a result of an improvement in treatment strategies. In 
the study by Yong-Xi Chen et al., with 101 patients, the 
mortality rate at 1 year was 18.8%, and 32.9% at 5 years.23 
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In the study by Day et al., with 390 patients including cas-
es of AAV and renal involvement, 18% of patients at 5 
years required renal replacement treatment and 40% died.21 
In our study, the mean follow-up was 4.1 years (1.5-12 
years) with a median of 3 years, during which 60% of pa-
tients underwent renal replacement therapy, and 12% 
died. Although the mean follow-up was shorter than in 
other studies, our mortality rates are low: 0% at 1 year fol-
low-up, one death (3.4%) after 3 years, and three deaths 
(10.3%) after 7 years.
Our study has several limitations. Since this is a ret-
rospective study, with consultation of physical and com-
puter medical records, there may have been misinterpre-
tations of data consulted, inducing bias especially in the 
calculation of BVAS and in the evaluation of symptoms 
presented by the patient at baseline. Another imitation 
is the fact that the evaluations of patients were not con-
ducted in a uniform manner with assessment intervals 
at an average of four months. During remissions, the av-
erage assessment intervals increased, and therefore mea-
surements may be under- or overvalued. Furthermore, 
since this is a study of patients followed only by the ne-
phrology service, there may be differences in the severity 
of the disease, types of ANCA antibodies and outcomes 
presented compared with the general population with 
AAV. A major limitation of our study was the small num-
ber of patients, which prevented us from obtaining sta-
tistical significance in the comparison of several variables 
among each other, a limitation inherent to the rarity of 
the disease.
conclusion
The vast majority of patients with AAV and renal involve-
ment are MPO-ANCA-positive (82.76%). Although there 
is no relationship between ANCA titers and the number 
of relapses, we found that PR3-ANCA-positive patients 
may occasionally be more likely to relapse, even if not sta-
tistically significantly. The fact that MPO-ANCA-positive 
patients have a mean CRP value within intervals signifi-
cantly lower than PR3-ANCA-positive patients allows us 
to infer a greater inflammatory activity of the latter that 
tends to support this hypothesis. Regarding the progres-
sion of ANCA titers from the date of diagnosis to the last 
evaluation, these tended to decline or remain constant 
regardless of the clinical outcome of patients. New pro-
spective studies that assess other markers would be of ex-
treme interest, including CXCL 13, MMP-3 and TIMP-1 
during disease activity and in response to treatment of 
AAV, in addition to the markers usually studied (securi-
ties ANCA, CRP and ESR), as well as the role of autoan-
tibodies to LAMP-2, plasminogen and moesin.
resuMo
Vasculite ANCA positiva: implicações clínicas dos tipos 
e dos títulos de ANCA
Introdução: a vasculite associada aos anticorpos antici-
toplasma de neutrófilos (ANCA) é uma doença autoimu-
ne que pode acometer vários órgãos, sendo o rim um dos 
mais afetados. Além dos ANCA serem marcadores de diag-
nóstico, foram também defendidos como marcadores de 
atividade. Recentemente as alterações genéticas encon-
tradas entre as poliangeítes serina-protease 3 da protei-
nase (PR3)-ANCA ou mieloperoxidase (MPO)-ANCA le-
vantam a possibilidade de diferenças imunopatogênicas 
e terapêuticas. 
Objetivos: identificar diferenças quanto a número de re-
cidivas, marcadores inflamatórios, desfechos e histologia 
renal relativamente aos tipos de ANCA. Analisar impli-
cações dos títulos de ANCA no prognóstico. 
Método: estudo retrospectivo observacional em hospi-
tal terciário português. 
Resultados: não se verificaram diferenças quanto à evo-
lução da função renal, ao padrão histológico e ao trata-
mento inicial relativamente aos subtipos de ANCA. Nos 
parâmetros analíticos avaliados, não se verificaram dife-
renças significativas relativas aos tipos de ANCA, à exce-
ção do valor médio de PCR no intervalo que foi de 6,3±1,3 
mg/L nos MPO-ANCA e 12,4±10,14 mg/L nos PR3-AN-
CA (p=0,04). Verificamos que 66,7% dos MPO-ANCA po-
sitivos não apresentaram recidivas versus 40% dos PR3-
-ANCA positivos. Não se verificou nenhuma correlação 
entre os títulos de ANCA à apresentação, durante a re-
missão e na última avaliação com o número de recidivas. 
Conclusão: os indivíduos PR3-ANCA apresentaram um 
valor médio de PCR nos intervalos superior aos indiví-
duos MPO-ANCA (p=0,04), o que parece evidenciar uma 
maior atividade inflamatória nos primeiros.
Palavras-chave: vasculite associada a anticorpo anticito-
plasma de neutrófilos, peroxidase, serina proteases.
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